Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)

Archimedes Development

Status: Unknown

Conditions: Breakthrough Cancer Pain

Treatments: Drug: PecFent® (fentanyl) nasal spray

Study type: Observational

Funder types: Industry

Identifiers

NCT01693328

CP057/11

Details and patient eligibility

About

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Adult (aged ≥18 years) with cancer
• Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain

Trial design

300 participants in 1 patient group

PecFent®

Treatment:

Drug: PecFent® (fentanyl) nasal spray